SARCOMA

ctDNA clearance and baseline detectability emerge as prognostic markers in the StrateGIST 1 trial; favorable ORRs seen in early-line cohorts.

The FDA granted the NDA for treatment of gastrointestinal stromal tumors with a PDUFA targeted action date of November 30, 2026.

The FDA awarded rare pediatric disease and orphan drug designation to the novel small molecule FL118 for osteosarcoma.

Rashmi Chugh, MD, discusses the outcomes and goals of a promising study for ozekibart plus chemotherapy in patients with relapsed Ewing sarcoma.

The oral gamma secretase inhibitor varegacestat improved progression-free survival and overall response rate vs placebo; full results to be presented at ASCO.

ODD status was granted based on tumor response rates with eftilagimod alfa and pembrolizumab of more than 3-fold above historical benchmarks from radiotherapy alone.

In patients with high-grade uterine sarcoma who achieved disease control, cabozantinib did not prolong survival and had added toxicity.

Ozekibart, irinotecan, and temozolomide yielded a high response rate and maintained tolerability in patients with relapsed/refractory Ewing sarcoma.

Ipsen pulls Tazverik worldwide after SYMPHONY-1 flags secondary blood cancer risk, halting trials and access programs and moving patients to standard care.

Erica Pimenta, MD, PhD, discussed the goals and key findings from her and her colleagues’ research into IGF-1 and GLP-1 signaling pathways in liposarcoma.

Tumor-infiltrating lymphocyte therapy yielded favorable results in a small cohort of patients with soft tissue sarcoma, leading to plans for a larger trial.

Cabozantinib plus temozolomide led to favorable short-term progression-free survival in a single-arm trial of patients with advanced leiomyosarcoma.

Although not as essential as in other tumor types, genomic testing is increasingly playing a role in guiding treatment for advanced sarcoma.

Recent trials reveal promising advancements in targeted therapies for chondrosarcomas and tenosynovial giant cell tumors.

The FDA gave breakthrough therapy designation to bezuclastinib plus sunitinib in imatinib-refractory gastrointestinal stromal tumors.

The FDA granted Orphan Drug Designation to LP-284, a small molecule targeting DNA damage repair mechanisms, for soft tissue sarcoma.

FDA fast tracks ADCE-D01, a promising treatment for soft tissue sarcoma, aiming to expedite patient access and improve survival rates.

During a live event, Steven I. Robinson, MBBS, discussed guideline-concordant active surveillance and systemic therapies for managing desmoid tumors.

FDA grants fast track designation to CLD-201, an innovative therapy for soft tissue sarcoma, enhancing its development and review process.

ASCO 2025 showcased breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new therapies for rare cancers.

A phase 2a trial shows tigilanol tiglate achieves an 80% response rate in soft tissue sarcoma, offering hope for effective treatment options.

Dale Shepard, MD, PhD, discusses the key themes emerging from the 2025 ASCO Annual Meeting, highlighting a prevailing sense of optimism driven by ongoing research.

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in progressive desmoid tumors.

The EFTISARC-NEO trial of eftilagimod alfa with radiotherapy and pembrolizumab in resectable soft tissue sarcoma achieved its primary end point.